VNDA Relative Valuation
VNDA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VNDA is overvalued; if below, it's undervalued.
Historical Valuation
Vanda Pharmaceuticals Inc (VNDA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -18.99. The fair price of Vanda Pharmaceuticals Inc (VNDA) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 5.27 USD , Vanda Pharmaceuticals Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：5.27
Fair
Undervalued
-2.43
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Vanda Pharmaceuticals Inc. (VNDA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 4.81. The thresholds are as follows: Strongly Undervalued below -8.57, Undervalued between -8.57 and -1.88, Fairly Valued between 11.51 and -1.88, Overvalued between 11.51 and 18.20, and Strongly Overvalued above 18.20. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.22
EV/EBIT
Vanda Pharmaceuticals Inc. (VNDA) has a current EV/EBIT of -0.22. The 5-year average EV/EBIT is 12.16. The thresholds are as follows: Strongly Undervalued below -24.40, Undervalued between -24.40 and -6.12, Fairly Valued between 30.44 and -6.12, Overvalued between 30.44 and 48.73, and Strongly Overvalued above 48.73. The current Forward EV/EBIT of -0.22 falls within the Historic Trend Line -Fairly Valued range.
1.22
PS
Vanda Pharmaceuticals Inc. (VNDA) has a current PS of 1.22. The 5-year average PS is 1.98. The thresholds are as follows: Strongly Undervalued below 0.31, Undervalued between 0.31 and 1.14, Fairly Valued between 2.81 and 1.14, Overvalued between 2.81 and 3.65, and Strongly Overvalued above 3.65. The current Forward PS of 1.22 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Vanda Pharmaceuticals Inc. (VNDA) has a current P/OCF of 0.00. The 5-year average P/OCF is 21.13. The thresholds are as follows: Strongly Undervalued below -162.20, Undervalued between -162.20 and -70.53, Fairly Valued between 112.80 and -70.53, Overvalued between 112.80 and 204.46, and Strongly Overvalued above 204.46. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.73
P/FCF
Vanda Pharmaceuticals Inc. (VNDA) has a current P/FCF of -2.73. The 5-year average P/FCF is 1.67. The thresholds are as follows: Strongly Undervalued below -10.07, Undervalued between -10.07 and -4.20, Fairly Valued between 7.55 and -4.20, Overvalued between 7.55 and 13.42, and Strongly Overvalued above 13.42. The current Forward P/FCF of -2.73 falls within the Historic Trend Line -Fairly Valued range.
Vanda Pharmaceuticals Inc (VNDA) has a current Price-to-Book (P/B) ratio of 0.67. Compared to its 3-year average P/B ratio of 0.57 , the current P/B ratio is approximately 17.75% higher. Relative to its 5-year average P/B ratio of 1.00, the current P/B ratio is about -33.31% higher. Vanda Pharmaceuticals Inc (VNDA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -15.64%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.44% , the current FCF yield is about -100.00% lower.
0.66
P/B
Median3y
0.57
Median5y
1.00
-26.64
FCF Yield
Median3y
-15.64
Median5y
-6.44
Competitors Valuation Multiple
The average P/S ratio for VNDA's competitors is 1.15, providing a benchmark for relative valuation. Vanda Pharmaceuticals Inc Corp (VNDA) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 18.06%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VNDA increased by 8.56% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -11.17 to -40.15.
The secondary factor is the Revenue Growth, contributed 18.06%to the performance.
Overall, the performance of VNDA in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Vanda Pharmaceuticals Inc (VNDA) currently overvalued or undervalued?
What is Vanda Pharmaceuticals Inc (VNDA) fair value?
How does VNDA's valuation metrics compare to the industry average?
What is the current P/B ratio for Vanda Pharmaceuticals Inc (VNDA) as of Dec 05 2025?
What is the current FCF Yield for Vanda Pharmaceuticals Inc (VNDA) as of Dec 05 2025?
What is the current Forward P/E ratio for Vanda Pharmaceuticals Inc (VNDA) as of Dec 05 2025?